On January 6, 2021, Tricida, Inc. as borrower, Hercules Capital, Inc., as administrative agent and each of the financial institutions party thereto as lenders (the “Lenders”) entered into the Sixth Amendment to Loan and Security Agreement to amend certain terms of the Loan and Security Agreement, dated as of February 28, 2018 (as amended by that certain First Amendment to Loan and Security Agreement and First Amendment to Warrants dated as of April 10, 2018, that certain Second Amendment to Loan and Security Agreement, dated as of October 15, 2018, that certain Third Amendment to Loan and Security Agreement, dated as of March 27, 2019, that certain Fourth Amendment to Loan and Security Agreement, dated as of March 31, 2020, that certain Fifth Amendment to Loan and Security Agreement, dated as of May 18, 2020 and the Sixth Amendment, the “Loan Agreement”, and the term loans thereunder, the “Term Loan”) by and among the Company, the Agent and the Lenders. The Sixth Amendment provides for, among other things, a decrease in the amount available under the Loan Agreement from $200.0 million to $75.0 million. The loan repayment schedule provides for interest only payments until April 1, 2022 (the “Amortization Date”), followed by consecutive equal monthly amortization payments of principal and interest through the maturity date. The maturity date of the Loan Agreement is October 1, 2023, subject to extension to April 1, 2024 on the condition that the Company obtains final approval from the U.S. Food and Drug Administration ("FDA") for the New Drug Application (“NDA”) for veverimer (also known as TRC101) on or before October 1, 2023. The Sixth Amendment also eliminates the 1.0% prepayment charge for prepayments of principal of the Term Loan made after March 1, 2021.